Ginkgo partners with Modulus to add to its cell therapy tool box

02 Apr 2024
firstwordpharma.com
Cell TherapyAcquisitionImmunotherapy
Ginkgo Bioworks has been on a cell-and-gene tool collecting spree this year, and its latest acquisition is Modulus Therapeutics’ library of switch receptors and CARs.
The suite of cell therapy components includes NK- and T-cell specific CAR and switch receptors, which are intended to improve the safety and efficacy of cell therapies by allowing for more precise control over activation and targeting.
The custom CARs are designed to enhance a cell therapy’s proliferation and cytotoxicity to generate a more robust and durable response against target cells.
The switch receptors use specific ligands to enable CAR-T or CAR-NK cell therapies to respond to environmental signals, including inhibitory ones.
Modulus’ tech will be integrated into Ginkgo's cell therapy service platform, which allows partners to sample CAR domains with various functional roles and structural positions, sourced from diverse immune cell types.
One such partner is Wisconsin Alumni Research Foundation, who linked up with Ginkgo last year to discover next-generation GD2 CAR-T cell therapies with improved persistence, proliferation, fitness to treat solid tumours.
Tuesday’s deal with Modulus follows a series of collaborations to bulk out the synthetic biology company’s genetic medicines offerings. Earlier this year, Ginkgo gained several key technologies, including ProteoNic’s vector production platform; Form Bio’s in silico suite for construct characterisation, simulation, and design optimization; and Patch Biosciences’s AI toolkit for DNA sequence design for more effective, specific, and durable genetic medicines.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.